文献速递消化系统肿瘤

拉罗替尼在TRK融合胃肠道肿瘤患者中的疗效与安全性

Efficacy and safety of larotrectinib in patients with TRK fusion gastrointestinal cancer.
PubMed 文献 · Eur J Cancer · 2025-03-04

该研究纳入NAVIGATE研究中的44例TRK融合胃肠道肿瘤患者,评估拉罗替尼的疗效与安全性。43例可评估患者的总缓解率为28%,结直肠癌患者为44%,中位缓解持续时间27个月,3/4级治疗相关不良事件发生率为16%,无治疗相关死亡。

要点

  • TRK融合胃肠道肿瘤患者接受拉罗替尼治疗,总缓解率为28%(95%CI 15-44)
  • 结直肠癌患者缓解率达44%(95%CI 24-65),中位总生存期29个月
  • 3/4级治疗相关不良事件发生率为16%,无治疗相关死亡

核心结论

  • 拉罗替尼在TRK融合胃肠道肿瘤患者中显示出持久缓解、延长生存和可控的安全性,包括MSI-H结直肠癌患者。
  • 该结果支持在胃肠道肿瘤患者中更广泛地采用二代测序检测NTRK基因融合。

研究设计与样本

  • 研究纳入NAVIGATE研究(NCT02576431)中的TRK融合胃肠道肿瘤患者。
  • 疗效由独立评审委员会(IRC)按RECIST v1.1评估。
  • 截至2023年7月,共纳入44例患者。

主要发现

  • 肿瘤类型包括结直肠癌(n=26)、胰腺癌(n=7)、胆管癌(n=4)、胃癌(n=3),以及阑尾癌、十二指肠癌、食管癌和肝癌各1例。
  • 26例结直肠癌患者中,16例(62%)已知微卫星高度不稳定(MSI-H)状态。
  • 43例IRC可评估患者中,所有患者的总缓解率为28%(95%CI 15-44),结直肠癌患者为44%(95%CI 24-65)。
  • 所有患者和结直肠癌患者的中位缓解持续时间均为27个月(95%CI 6-不可估计[NE])。
  • 所有患者的中位无进展生存期为6个月(95%CI 5-9),结直肠癌患者为7个月(95%CI 6-NE);所有患者的中位总生存期为13个月(95%CI 7-29),结直肠癌患者为29个月(95%CI 7-NE)。

临床怎么用

  • 作者认为,该结果支持在胃肠道肿瘤患者中更广泛地采用二代测序检测NTRK基因融合。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Larotrectinib is the first-in-class, highly selective TRK inhibitor with demonstrated efficacy in various TRK fusion solid tumours. We report the efficacy and safety of larotrectinib in patients with TRK fusion gastrointestinal (GI) cancer. METHODS: Patients with TRK fusion GI cancer from NAVIGATE (NCT02576431) were included. Response was independent review committee (IRC)-assessed per RECIST v1.1. RESULTS: As of July 2023, 44 patients were enrolled. Tumour types included colorectal (CRC; n = 26), pancreatic (n = 7), cholangiocarcinoma (n = 4), gastric (n = 3), and one each of appendiceal, duodenal, oesophageal and hepatic cancers. Of the 26 patients with CRC, 16 (62 %) had known microsatellite instability-high (MSI-H) status. For the 43 IRC-eligible patients, overall response rate was 28 % (95 % confidence interval [CI] 15-44) for all patients and 44 % (95 % CI 24-65) for those with CRC. In patients overall and in those with CRC, median duration of response was 27 months (95 % CI 6-not estimable [NE]) and 27 months (95 % CI 6-NE), median progression-free survival was 6 months (95 % CI 5-9) and 7 months (95 % CI 6-NE), and median overall survival was 13 months (95 % CI 7-29) and 29 months (95 % CI 7-NE), respectively. Grade 3/4 treatment-related adverse events (TRAEs) occurred in seven (16 %) patients. There were no deaths due to TRAEs. CONCLUSION: Larotrectinib demonstrated long durability, extended survival and manageable safety in patients with TRK fusion GI cancer, including those with MSI-H CRC. This supports the wider adoption of next-generation sequencing testing for NTRK gene fusions in patients with GI cancer.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Qi C, Shen L, Andre T, et al. Efficacy and safety of larotrectinib in patients with TRK fusion gastrointestinal cancer. Eur J Cancer. 2025. PMID: 40068370. doi:10.1016/j.ejca.2025.115338

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。